Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 9/20 | 0.53 |
| ▸ | HINT1 | P49773 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19128529 | 1.00 | TYMP (0.53) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL28827056 | 0.91 | TYMP (0.54) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL19127268 | 0.89 | TYMP (0.63) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL17223100 | 0.88 | TYMP (0.64) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL19127168 | 0.88 | TYMP (0.47) | TYMPHINT1HPGDNT5E | |
| SCHEMBL20637781 | 0.86 | ADORA1 (0.50) | TYMPNT5E | |
| SCHEMBL19146315 | 0.85 | HINT1 (0.55) | HINT1HPGDTAS1R3TAS1R1GSK3A | |
| SCHEMBL19127992 | 0.84 | TYMP (0.52) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL19127991 | 0.84 | TYMP (0.52) | TYMPHINT1HPGDTAS1R3TAS1R1 | |
| SCHEMBL16702978 | 0.82 | TYMP (0.68) | TYMPHINT1HPGDTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | TYMP 2613/4885HINT1 1249/4885HPGD 1546/4885 |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TYMP 2613/4885HINT1 1249/4885HPGD 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.